Waldencast, the parent company of Milk Makeup and Obagi Medical, is making exciting strides in the aesthetic and dermatological space by acquiring Novaestiq Corp. This innovative company specializes in aesthetic and medical solutions, bringing with it the U.S. rights to the Saypha line of hyaluronic acid injectable gels. While specific terms of the deal remain undisclosed, this acquisition marks a significant expansion for the Obagi brand, diversifying its offerings from just skincare products to include dermal fillers in the U.S. market.
Michel Brousset, co-founder and CEO of Waldencast, expressed enthusiasm about this development, stating that it enables the company to broaden Obagi Medical’s portfolio with consumer-focused injectable procedures. By incorporating these proven products into their lineup, Waldencast aims to enhance its market reach. This move not only responds to the growing demand for aesthetic treatments but also assures professionals and patients that they can expect quality and trusted solutions under the Obagi brand.
The Saypha line, developed by Croma-Pharma GmbH in Austria, boasts widespread recognition, being marketed in over 80 countries, although it’s still pending approval from the U.S. Food and Drug Administration. Saypha’s unique technology is designed to deliver superior hyaluronic acid treatments through an advanced 3D matrix. This innovation promises to facilitate natural-looking results while maintaining optimal gel properties, making it an appealing option for both providers and patients.
Dr. Suzan Obagi, the chief medical director at Obagi Medical, highlights the importance of combining quality skincare with injectable solutions for optimal outcomes. The integration of Saypha injectables allows professionals to offer more personalized care, enhancing the quality and safety of aesthetic treatments for their clients. She emphasizes that great results stem from excellent skincare, enriched through effective after-care, which can be achieved when injectables are administered by qualified practitioners.
Brousset envisions the Obagi brand as a cornerstone in the aesthetics industry. He believes that positioning Saypha under the Obagi name will significantly enhance its market performance. He aspires to transform Obagi into a mega brand in beauty aesthetics, leveraging the established trust that both physicians and consumers have in the Obagi name. By creating a robust platform for aesthetic marketing, Waldencast aims to foster confidence in their offerings.
Looking ahead, Brousset is receptive to further merger and acquisition opportunities, particularly in the aesthetics field. He views this acquisition as a foundational step into the realm of aesthetics, signaling a commitment to pursuing additional ventures that will cement Obagi’s status as a leading name in the beauty industry. The future looks promising for Obagi as it continues to innovate and expand its services, reinforcing its legacy in skincare and aesthetic treatments.